top of page
Giens_Banner.png
ESGCT_logo_blue_vertical_office_edited.png
ESGCT_SpringSchool2023_type_WHITEYELLOW.png
SFTCG Simple_edited.png

SPRING SCHOOL PROGRAMME

Check the programme regularly for updates

Tue

Tuesday 28 March

15:00-16:30

Registration

16.30-19.00

Workshops (40 students per workshop)

16:30-19:00

Workshop 1: Form your own opinion – how to judge a scientific publication

Hildegard Büning, ESGCT Education & Training

Els Verhoeyen, President, SFTCG, Board Member, ESGCT

16:30-19:00

Workshop 2: How to write a scientific manuscript

Leszek Lisowski - University of Sydney

Thomas Gallagher - Human Gene Therapy

​

16:30-19:00

Workshop 3: Ethical consideration in experimental, pre-clinical and clinical gene therapy

Frank Staal, University of Leiden

​

​

19:30

Dinner

Wed

Wednesday 29 March

08:30-09:00

Welcome Address

Juan Bueren (President, ESGCT)

Els Verhoeyen (President, SFTCG, Board Member, ESGCT)

Hildegard Büning (ESGCT Education & Training)

​

09:00-10:00

Keynote

INV01: Juan Bueren, Ciemat Madrid

Moving from Concept to Clinical Reality – 33 years from the first human clinical trial to now

​

10:00-11:20

Session 1: Gene therapy tools - insights by experts (LV)

INV02: Axel Schambach, Hannover Medical School

What you should know about retro/lentiviral vector design

INV03: Els Verhoeyen, University of Nice

How to improve nature – the next generation of lentiviral vectors

11:20-11:50
Coffee Break

11:50-12:50

Keynote

INV04: Frank Staal, Leiden University

Developing  stem cell based gene therapy for Recombinase deficiencies

12:50-13:50
Lunch

13:50-15:00
Team building activity

15:00-16:20

Session 2:

Gene therapy tools - insights by experts (AAV)

INV05: Hildegard Büning, Hannover Medical School

Almost a virus – the adeno-associated virus (AAV) vector system

INV06: Leszek Lesowski, University of Sydney

How to improve nature – the next generation of AAV vectors

​

16:20-17:20

Keynote

INV07: Gloria Gonzalez-Aseguinolaza, FIMA Pamplona

Liver-directed Gene Therapy – the long journey to the market

​

17:20-17:50
Coffee Break

17:50-19:10

Session 3: Gene therapy tools - insights by experts (non-viral vectors)

INV08: Pieter Vader, University Medical Center Utrecht

Extracellular vesicles

INV09: Tristan Montier, University of Brest

Fine-tuning of nanoparticles for aerosol gene transfer: applications to cystic fibrosis

19:30
Dinner

20:30 After dinner keynote

INV10: Nathalie Cartier, AskBio, Paris
Gene Therapy for neurodegenerative diseases from genetic to complex diseases : delivery and targets

Thu

Thursday 30 March

09:00-10:00

Keynote

INV11Toni Cathomen, University Hospital Freiburg

Risk assessment of gene editing associated off-target effects

​

10:00-11:20

Session 4: Gene Therapy 2.0 – The Age of precision Gene Therapy

INV12Paula Rio, Ciemat Madrid

Gene editing is coming to life as treatment strategy in Fanconi anemia

INV13: Matthias Titeux, Institut Imagine, Paris

Gene editing strategies for rare skin disorders

11:20-11:50
Coffee Break

11:50 -12:50

Keynote

INV14: Anne Galy, Genethon, Evry

The immune system does not like it to be tricked

​

12:50-13:50
Lunch

13:50-15:00
Team building activity

15:00-16:20

Session 5: The payload

INV15: Zoltan Ivics, Paul Ehrlich Institute, Langen

Wide awake and ready to move: non-viral genome engineering with Sleeping Beauty transposon vectors

INV14: Ivana Trapani, Tigem Naples

How to deliver large genomes in a too small vehicle

​

16:20 -17:20

Keynote

INV16: Vincenzo Cerullo, University of Helsinki

Dressing viruses in tumor’s clothing – new strategies in anti-tumor therapy

17:20-17:50
Coffee Break

17:50-19:10

Session 6: Fighting cancer with novel weapons

INV17: Andrea Schmidts, Technical University of Munich

CAR-T cells – how to make a living drug

INV18: Eliana Ruggiero, HSR, Milan

The world beyond CAR T cells

19:30
Dinner

Fri

Friday 31 March

09.00-10.00

Keynote

INV19 Alberto Auricchio, Tigem Naples

Vision – Gene Therapy for fighting blindness

10.00-10.30
Coffee Break

10:30-11.50

Session 7: Pre-clinical and clinical gene therapy

INV20: Giuliana Ferrari, SR Tiget, Milan

Gene therapy for hemoglobinopathies: past, present and future

INV21: Alessandro Aiuti, HSR Tiget, Milan

Gene Therapy for primary immunodeficiencies, the prime target for lentiviral vector ex vivo gene therapy, is reaching its next level

​

11:50-12.50

Keynote

INV22: Claire Booth, UCLondon

It is all about accessibility

​

12:50

Closing

​

Juan Bueren, Hildegard Büning & Els Verhoeyen

bottom of page